Table 1.

Baseline characteristics of adult patients with psoriasis by treatment groups

Patients characteristics	Topical treatmentsa		Non-biological systemic treatmentb		Biological treatmentc
	Number	Percent	Number	Percent	Number	Percent
	70796		11919		2147
Age (years) at first dispensing at index date
<30	7005	9.9	983	8.3	326	15.2
30–39	9323	13.2	1678	14.1	484	22.5
40–49	11347	16.0	2508	21.0	543	25.3
50–59	14999	21.2	3008	25.2	478	22.3
60–69	16109	22.8	2505	21.0	266	12.4
70–79	8272	11.7	1001	8.4	47	2.2
≥80	3741	5.3	236	2.0	3	0.1
Median (IQR)	55.0 (41–66)		52.0 (41–62)		44.0 (34–55)
Year of first dispensing
2007d	5525	7.8	776	6.5	49	2.3
2008	10936	15.5	1682	14.1	220	10.3
2009	11470	16.2	1715	14.4	231	10.7
2010	11950	16.9	1834	15.4	289	13.5
2011	11415	16.1	2002	16.8	382	17.7
2012	10540	14.9	1972	16.6	442	20.6
2013	8960	12.7	1938	16.3	534	24.9
Number of outpatient visits within 1 year before index date
0	34835	49.2	3941	33.1	503	23.4
1	12844	18.1	2179	18.3	298	13.9
2	7537	10.7	1488	12.5	269	12.5
3+	15580	22.0	4311	36.2	1077	50.2
Mean (±SD)	1.7 (±4.1)		2.9 (±5.1)		4.1 (±5.4)
Median (IQR)	1 (0–2)		1 (0–4)		3 (1–6)

Notes:

^aTopical treatment with calcipotriol or calcipotriol combinations.

^bNon-biological systemic treatment with methotrexate, cyclosporine, acitretin and phototherapy.

^cBiological treatment with adalimumab, etanercept, infliximab, efalizumab, ustekinumab, certolizumab, golimumab.

^dPatients identified in 2007 were only captured in the study population if they had an index date on or after 1st July 2007.

Abbreviation: IQR, interquartile range.